C-GNMMYap Therapeutics
AAV gene therapy, Hippo/YAP modulation, advanced biologics
repairinggene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-GNMM
C-GNMMC-GNMMAAV gene therapy, Hippo/YAP modulation, advanced biologics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Yap Therapeutics AAV gene therapy, Hippo/YAP modulation, advanced biologics
Medley Therapeutics, formerly known as YAP Therapeutics, describes a dual-platform approach using genetic medicine and advanced biologics. Its genetic medicine platform aims to activate innate regenerative pathways, including cardiac regeneration through Hippo/YAP signaling modulation. Its advanced biologics platform targets fibrosis and solid tumor cancers.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Yap Therapeutics — Early mechanism · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic